This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Opexa To Participate At Upcoming Industry Conferences

Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing Tcelna , a novel T-cell therapy for multiple sclerosis (MS), today announced that Neil Warma, President and Chief Executive Officer, will participate in two upcoming industry conferences. Details regarding these events are as follows:

Intellectual Property Owners Association (IPO) Annual Meeting

This conference will take place September 9-11, 2012 at the JW Marriott Hill Country in San Antonio, Texas.

        --   Keynote Luncheon Address
Delivered by Mr. Warma
Tuesday, September 11, 2012, 12:00 – 1:30 p.m. CT

Each year, the organizers of the IPO Annual Meeting invite one CEO to deliver a keynote luncheon address. This year, Mr. Warma has been selected to provide insight on the role of intellectual property rights from the perspective of business.

The 8 th Annual Burrill Personalized Medicine Meeting

This meeting of researchers, drug developers, analysts, investors and other life science industry representatives will take place September 13-14, 2012 at the Bentley Reserve & Conference Center in San Francisco.

        --   “Personalized Medicine From a Drug Developer’s Point of View”
Panel participation by Mr. Warma
Friday, September 14, 2012, 9:30 – 10:30 a.m. PT

Mr. Warma will join several additional panelists as they discuss the implications that advances in personalized medicine are having on the drug development business. Mr. Warma will share Opexa’s experiences regarding the clinical development of Tcelna, the first ever personalized T-cell therapy for MS patients.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,063.93 +120.12 0.71%
S&P 500 1,977.34 +9.77 0.50%
NASDAQ 4,438.7230 +23.2330 0.53%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs